Off Time Independently Affects Quality of Life in Advanced Parkinson’s Disease (APD) Patients but Not in Non-APD Patients: Results from the Self-Reported Japanese Quality-of-Life Survey of Parkinson’s Disease (JAQPAD) Study
Yuka Hayashi
Department of Neurology, Faculty of Medicine, Fukuoka University, 7-45-1 Nanakuma, Johnan-ku, Fukuoka 814-0180, Japan fukuoka-u.ac.jp
Search for more papers by this authorRyoko Nakagawa
Medical, AbbVie GK, 3-1-21 Shibaura, Minato-ku, Tokyo 108-0023, Japan
Search for more papers by this authorMiwako Ishido
Medical, AbbVie GK, 3-1-21 Shibaura, Minato-ku, Tokyo 108-0023, Japan
Search for more papers by this authorYoko Yoshinaga
Medical, AbbVie GK, 3-1-21 Shibaura, Minato-ku, Tokyo 108-0023, Japan
Search for more papers by this authorJun Watanabe
Medical, AbbVie GK, 3-1-21 Shibaura, Minato-ku, Tokyo 108-0023, Japan
Search for more papers by this authorKanako Kurihara
Department of Neurology, Faculty of Medicine, Fukuoka University, 7-45-1 Nanakuma, Johnan-ku, Fukuoka 814-0180, Japan fukuoka-u.ac.jp
Search for more papers by this authorKoichi Nagaki
Department of Neurology, Faculty of Medicine, Fukuoka University, 7-45-1 Nanakuma, Johnan-ku, Fukuoka 814-0180, Japan fukuoka-u.ac.jp
Search for more papers by this authorHiromu Ogura
Department of Neurology, Faculty of Medicine, Fukuoka University, 7-45-1 Nanakuma, Johnan-ku, Fukuoka 814-0180, Japan fukuoka-u.ac.jp
Search for more papers by this authorTakayasu Mishima
Department of Neurology, Faculty of Medicine, Fukuoka University, 7-45-1 Nanakuma, Johnan-ku, Fukuoka 814-0180, Japan fukuoka-u.ac.jp
Search for more papers by this authorShinsuke Fujioka
Department of Neurology, Faculty of Medicine, Fukuoka University, 7-45-1 Nanakuma, Johnan-ku, Fukuoka 814-0180, Japan fukuoka-u.ac.jp
Search for more papers by this authorCorresponding Author
Yoshio Tsuboi
Department of Neurology, Faculty of Medicine, Fukuoka University, 7-45-1 Nanakuma, Johnan-ku, Fukuoka 814-0180, Japan fukuoka-u.ac.jp
Search for more papers by this authorYuka Hayashi
Department of Neurology, Faculty of Medicine, Fukuoka University, 7-45-1 Nanakuma, Johnan-ku, Fukuoka 814-0180, Japan fukuoka-u.ac.jp
Search for more papers by this authorRyoko Nakagawa
Medical, AbbVie GK, 3-1-21 Shibaura, Minato-ku, Tokyo 108-0023, Japan
Search for more papers by this authorMiwako Ishido
Medical, AbbVie GK, 3-1-21 Shibaura, Minato-ku, Tokyo 108-0023, Japan
Search for more papers by this authorYoko Yoshinaga
Medical, AbbVie GK, 3-1-21 Shibaura, Minato-ku, Tokyo 108-0023, Japan
Search for more papers by this authorJun Watanabe
Medical, AbbVie GK, 3-1-21 Shibaura, Minato-ku, Tokyo 108-0023, Japan
Search for more papers by this authorKanako Kurihara
Department of Neurology, Faculty of Medicine, Fukuoka University, 7-45-1 Nanakuma, Johnan-ku, Fukuoka 814-0180, Japan fukuoka-u.ac.jp
Search for more papers by this authorKoichi Nagaki
Department of Neurology, Faculty of Medicine, Fukuoka University, 7-45-1 Nanakuma, Johnan-ku, Fukuoka 814-0180, Japan fukuoka-u.ac.jp
Search for more papers by this authorHiromu Ogura
Department of Neurology, Faculty of Medicine, Fukuoka University, 7-45-1 Nanakuma, Johnan-ku, Fukuoka 814-0180, Japan fukuoka-u.ac.jp
Search for more papers by this authorTakayasu Mishima
Department of Neurology, Faculty of Medicine, Fukuoka University, 7-45-1 Nanakuma, Johnan-ku, Fukuoka 814-0180, Japan fukuoka-u.ac.jp
Search for more papers by this authorShinsuke Fujioka
Department of Neurology, Faculty of Medicine, Fukuoka University, 7-45-1 Nanakuma, Johnan-ku, Fukuoka 814-0180, Japan fukuoka-u.ac.jp
Search for more papers by this authorCorresponding Author
Yoshio Tsuboi
Department of Neurology, Faculty of Medicine, Fukuoka University, 7-45-1 Nanakuma, Johnan-ku, Fukuoka 814-0180, Japan fukuoka-u.ac.jp
Search for more papers by this authorAbstract
Introduction. Parkinson’s disease (PD) is characterized by a triad of motor symptoms and several nonmotor symptoms (NMS). Identifying the most appropriate treatment is essential for improving patient quality of life (QoL). However, it is still not known which PD symptoms more commonly affect patients with advanced PD (APD) versus non-APD. This study examined the factors that most affected the QoL of patients with APD (defined using the 5-2-1 criteria: ≥5 oral levodopa doses a day, off time ≥2 hours a day, or troublesome dyskinesia ≥1 hour a day) versus non-APD in a large Japanese population using the Japanese Quality-of-Life Survey of Parkinson’s Disease (JAQPAD) study. Methods. Participants in this self-reported survey-based study included all members of the Japan Parkinson’s Disease Association. Questionnaires assessing NMS and QoL (e.g., the 8-item PD Questionnaire [PDQ-8]) were included. Univariate and multivariate regression analyses were conducted to identify clinical factors impacting QoL using the PDQ-8 Summary Index (PDQ-8 SI). Results. Of the 3022 eligible patients, 864 were classified as having non-APD and 1599 as having APD. QoL as assessed by the PDQ-8 SI was notably worse in patients with APD versus non-APD (39.2 vs. 26.9, p < 0.0001). Although off time affected QoL only in patients with APD, PD duration and the NMS Questionnaire score significantly contributed to the QoL in both patients with APD and non-APD. Conclusions. This study identified the factors more commonly associated with worse QoL in patients with APD versus non-APD. Our findings offer new insights for providing optimal treatment and improving treatment satisfaction in patients with PD.
Conflicts of Interest
Y. Tsuboi has served as an advisor for AbbVie GK and has received research support from the Japan Agency for Medical Research and Development and Kyowa Kirin. R. Nakagawa and J. Watanabe are employees of AbbVie GK and may receive stock or stock options. M. Ishido and Y. Yoshinaga are former employees of AbbVie GK. Y. Hayashi, K. Kurihara, K. Nagaki, H. Ogura, T. Mishima, and S. Fujioka declare no conflicts of interest.
Open Research
Data Availability
The data generated and/or analyzed during the current study that were used to support the findings of the study were supplied by AbbVie under license and therefore cannot be made freely available. Requests for access to these data should be made to the corresponding author.
Supporting Information
| Filename | Description |
|---|---|
| padi9917539-sup-0001-f1.docxWord 2007 document , 50.5 KB | Supplementary Materials Table S1: Multiple regression analysis for PDQ-8 SI. Table S2: Baseline demographics and clinical characteristics of patients meeting (+) or not meeting (−) all of the 5-2-1 criteria. Table S3: Baseline demographics of patients with APD meeting (+) or not meeting (−) each of the 5-2-1 criteria. Table S4: PDQ-8 SI score assessed in patients with APD meeting (+) or not meeting (−) each of the 5-2-1 criteria. |
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
References
- 1 GBD 2016 Parkinson’s Disease Collaborators, Global, regional, and national burden of Parkinson’s disease, 1990–2016: a systematic analysis for the global burden of disease study 2016, The Lancet Neurology. (2018) 17, no. 11, 939–953.
- 2 Osaki Y., Morita Y., Kuwahara T., Miyano I., and Doi Y., Prevalence of Parkinson’s disease and atypical parkinsonian syndromes in a rural Japanese district, Acta Neurologica Scandinavica. (2011) 124, no. 3, 182–187, https://doi.org/10.1111/j.1600-0404.2010.01442.x, 2-s2.0-79961205551.
- 3 Hughes A. J., Daniel S. E., Kilford L., and Lees A. J., Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases, Journal of Neurology, Neurosurgery & Psychiatry. (1992) 55, no. 3, 181–184, https://doi.org/10.1136/jnnp.55.3.181, 2-s2.0-0026514953.
- 4 Titova N., Martinez-Martin P., Katunina E., and Chaudhuri K. R., Advanced Parkinson’s or “complex phase” Parkinson’s disease? re-evaluation is needed, Journal of Neural Transmission. (2017) 124, no. 12, 1529–1537.
- 5 Carrarini C., Russo M., Dono F., Pietro M. D., Rispoli M. G., Stefano V. D., Ferri L., Barbone F., Vitale M., Thomas A., Sensi S. L., Onofrj M., and Bonanni L., A stage-based approach to therapy in Parkinson’s disease, Biomolecules. (2019) 9, no. 8.
- 6 Chaudhuri K. R., Healy D. G., Schapira A. H., and National Institute for Clinical Excellence, Non-motor symptoms of Parkinson’s disease: diagnosis and management, The Lancet Neurology. (2006) 5, no. 3, 235–245, https://doi.org/10.1016/s1474-4422(06)70373-8, 2-s2.0-32544432029.
- 7 Varanese S., Birnbaum Z., Rossi R., and Rocco A. D., Treatment of advanced Parkinson’s disease, Parkinson’s Disease. (2010) 2010, 10, 480260, https://doi.org/10.4061/2010/480260, 2-s2.0-79953290728.
- 8 Poewe W. and Mahlknecht P., The clinical progression of Parkinson’s disease, Parkinsonism & Related Disorders. (2009) 15, no. S4, S28–S32, https://doi.org/10.1016/s1353-8020(09)70831-4, 2-s2.0-72649106902.
- 9 Riedel O., Klotsche J., Wittchen H.-U., and GEPAD Study Group, Motor impairment, depression, dementia: which forms the impression of disease severity in Parkinson’s disease?, Parkinsonism and Related Disorders. (2014) 20, no. 12, 1365–1370, https://doi.org/10.1016/j.parkreldis.2014.09.025, 2-s2.0-84915786390.
- 10 Martínez-Martín P., Rodríguez-Blázquez C., Alvarez M., Arakaki T., Arillo V. C., Chaná P., Fernández W., Garretto N., Martínez-Castrillo J. C., Rodríguez-Violante M., Serrano-Dueñas M., Ballesteros D., Rojo-Abuin J. M., Chaudhuri K. R., and Merello M., Parkinson’s disease severity levels and MDS-unified Parkinson’s disease rating scale, Parkinsonism and Related Disorders. (2015) 21, no. 1, 50–54, https://doi.org/10.1016/j.parkreldis.2014.10.026, 2-s2.0-84918574785.
- 11 Luquin M. R., Kulisevsky J., Martinez-Martin P., Mir P., and Tolosa E. S., Consensus on the definition of advanced Parkinson’s disease: a neurologists-based Delphi study (CEPA study), Parkinson’s Disease. (2017) 2017, 8, 4047392, https://doi.org/10.1155/2017/4047392, 2-s2.0-85012190883.
- 12 World Health Organization, International Statistical Classification of Diseases and Related Health Problems 10th Revision (ICD-10) Version 2019, ICD Revision Topic Advisory Groups, 2021, World Health Organization, Geneva, Switzerland, https://icd.who.int/browse10/2019/en#/G20.
- 13 Hassan A., Wu S. S., Schmidt P., Simuni T., Giladi N., Miyasaki J. M., Bloem B. R., Malaty I. A., and Okun M. S., The profile of long-term Parkinson’s disease survivors with 20 years of disease duration and beyond, Journal of Parkinson’s Disease. (2015) 5, no. 2, 313–319, https://doi.org/10.3233/jpd-140515, 2-s2.0-84930516940.
- 14 Antonini A., Stoessl A. J., Kleinman L. S., Skalicky A. M., Marshall T. S., Sail K. R., Onuk K., and Odin P. L. A., Developing consensus among movement disorder specialists on clinical indicators for identification and management of advanced Parkinson’s disease: a multi-country Delphi-panel approach, Current Medical Research and Opinion. (2018) 34, no. 12, 2063–2073, https://doi.org/10.1080/03007995.2018.1502165, 2-s2.0-85052075848.
- 15 Fasano A., Fung V. S. C., Lopiano L., Elibol B., Smolentseva I. G., Seppi K., Takáts A., Onuk K., Parra J. C., Bergmann L., Sail K., Jalundhwala Y., and Pirtosek Z., Characterizing advanced Parkinson’s disease: OBSERVE-PD observational study results of 2615 patients, BMC Neurology. (2019) 19, no. 1.
- 16
Martínez-Martin P.,
Stocchi F., and
Reichmann H., Quality of life in Parkinson’s disease—patient, clinical and research perspectives, European Neurological Review. (2014) 9, no. 1, 12–18.
10.17925/ENR.2014.09.01.12 Google Scholar
- 17 Abbas M. M., Xu Z., and Tan L. C. S., Epidemiology of Parkinson’s disease-east versus west, Movement Disorders Clinical Practice. (2018) 5, no. 1, 14–28, https://doi.org/10.1002/mdc3.12568, 2-s2.0-85060170262.
- 18 Morioka S., Sakata K., Yoshida S., Nakai E., Shiba M., Yoshimura N., and Hashimoto T., Incidence of Parkinson disease in Wakayama, Japan, Journal of Epidemiology. (2002) 12, no. 6, 403–407, https://doi.org/10.2188/jea.12.403, 2-s2.0-0036831196.
- 19 Kurihara K., Nakagawa R., Ishido M., Yoshinaga Y., Watanabe J., Hayashi Y., Mishima T., Fujioka S., and Tsuboi Y., Impact of motor and nonmotor symptoms in Parkinson disease for the quality of life: the Japanese Quality-of-Life Survey of Parkinson Disease (JAQPAD) study, Journal of the Neurological Sciences. (2020) 419, 6, 117172.
- 20 International Society for Pharmacoepidemiology, Guidelines for good pharmacoepidemiology practices (GPP), International Society for Pharmacoepidemiology, Bethesda, MD, USA, 2020, https://www.pharmacoepi.org/resources/policies/guidelines-08027/.
- 21 Stocchi F., Antonini A., Barone P., Tinazzi M., Zappia M., Onofrj M., Ruggieri S., Morgante L., Bonuccelli U., Lopiano L., Pramstaller P., Albanese A., Attar M., Posocco V., Colombo D., and Abbruzzese G., Early DEtection of wEaring off in Parkinson disease: the DEEP study, Parkinsonism and Related Disorders. (2014) 20, no. 2, 204–211, https://doi.org/10.1016/j.parkreldis.2013.10.027, 2-s2.0-84893681784.
- 22 Rodríguez-Violante M., Ospina-García N., Dávila-Avila N. M., Cruz-Fino D., Cruz-Landero A. d. l., and Cervantes-Arriaga A., Motor and non-motor wearing-off and its impact in the quality of life of patients with Parkinson’s disease, Arquivos de Neuro-psiquiatria. (2018) 76, no. 8, 517–521, https://doi.org/10.1590/0004-282x20180074, 2-s2.0-85053634112.
- 23 Santos-Garcia D., de Deus Fonticoba T., Suarez Castro E., Aneiros Diaz A., and McAfee D., 5-2-1 criteria: a simple screening tool for identifying advanced PD patients who need an optimization of Parkinson’s treatment, Parkinson’s Disease. (2020) 2020, 6, 7537924, https://doi.org/10.1155/2020/7537924.
- 24 Marras C., Rochon P., and Lang A. E., Predicting motor decline and disability in Parkinson disease: a systematic review, Archives of Neurology. (2002) 59, no. 11, 1724–1728, https://doi.org/10.1001/archneur.59.11.1724, 2-s2.0-0036846580.
- 25 Mahajan A., Chirra M., Dwivedi A. K., Sturchio A., Keeling E. G., Marsili L., and Espay A. J., Skin cancer may delay onset but not progression of Parkinson’s disease: a nested case-control study, Frontiers in Neurology. (2020) 11, https://doi.org/10.3389/fneur.2020.00406.
- 26 Bloem B. R., Okun M. S., and Klein C., Parkinson’s disease, The Lancet. (2021) 397, no. 10291, 2284–2303, https://doi.org/10.1016/s0140-6736(21)00218-x.
- 27 Kimura H., Kurimura M., Wada M., Kawanami T., Kurita K., Suzuki Y., Katagiri T., Daimon M., Kayama T., and Kato T., Female preponderance of Parkinson’s disease in Japan, Neuroepidemiology. (2002) 21, no. 6, 292–296, https://doi.org/10.1159/000065527, 2-s2.0-0036967931.
- 28 Yamawaki M., Kusumi M., Kowa H., and Nakashima K., Changes in prevalence and incidence of Parkinson’s disease in Japan during a quarter of a century, Neuroepidemiology. (2009) 32, no. 4, 263–269, https://doi.org/10.1159/000201565, 2-s2.0-59649097630.
- 29 Ouma S., Fukae J., Fujioka S., Yamamoto S., Hatano T., Yoritaka A., Okuma Y., Kashihara K.-I., Hattori N., and Tsuboi Y., The risk factors for the wearing-off phenomenon in Parkinson’s disease in Japan: a cross-sectional, multicenter study, Internal Medicine (Tokyo, Japan). (2017) 56, no. 15, 1961–1966.
- 30 Bower J. H., Maraganore D. M., McDonnell S. K., and Rocca W. A., Influence of strict, intermediate, and broad diagnostic criteria on the age- and sex-specific incidence of Parkinson’s disease, Movement Disorders. (2000) 15, no. 5, 819–825, https://doi.org/10.1002/1531-8257(200009)15:5<819::aid-mds1009>3.0.co;2-p.
- 31 Baldereschi M., Di Carlo A., Rocca W. A., Vanni P., Maggi S., Perissinotto E., Grigoletto F., Amaducci L., and Inzitari D., Parkinson’s disease and parkinsonism in a longitudinal study: two-fold higher incidence in men. ILSA working group. Italian longitudinal study on aging, Neurology. (2000) 55, no. 9, 1358–1363, https://doi.org/10.1212/wnl.55.9.1358, 2-s2.0-0034649437.
- 32 Antonini A., Robieson W. Z., Bergmann L., Yegin A., and Poewe W., Age/disease duration influence on activities of daily living and quality of life after levodopa-carbidopa intestinal gel in Parkinson’s disease, Neurodegenerative Disease Management. (2018) 8, no. 3, 161–170, https://doi.org/10.2217/nmt-2017-0046, 2-s2.0-85050494013.
- 33 Khoo T. K., Yarnall A. J., Duncan G. W., Coleman S., O’Brien J. T., Brooks D. J., Barker R. A., and Burn D. J., The spectrum of nonmotor symptoms in early Parkinson disease, Neurology. (2013) 80, no. 3, 276–281, https://doi.org/10.1212/wnl.0b013e31827deb74, 2-s2.0-84873660450.
- 34 Barone P., Antonini A., Colosimo C., Marconi R., Morgante L., Avarello T. P., Bottacchi E., Cannas A., Ceravolo G., Ceravolo R., Cicarelli G., Gaglio R. M., Giglia R. M., Iemolo F., Manfredi M., Meco G., Nicoletti A., Pederzoli M., Petrone A., Pisani A., Pontieri F. E., Quatrale R., Ramat S., Scala R., Volpe G., Zappulla S., Bentivoglio A. R., Stocchi F., Trianni G., and Dotto P. D., The PRIAMO study: a multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson’s disease, Movement Disorders. (2009) 24, no. 11, 1641–1649, https://doi.org/10.1002/mds.22643, 2-s2.0-69949153066.
- 35 Cools C. I., de Vries N. M., and Bloem B. R., Happiness: a novel outcome in Parkinson studies?, Journal of Parkinson’s Disease. (2020) 10, no. 3, 1261–1266, https://doi.org/10.3233/jpd-201999.
- 36 Marsili L., Bologna M., Miyasaki J. M., and Colosimo C., Device-aided therapies for advanced Parkinson disease: insights from an international survey, Neurological Sciences. (2021) 42, no. 7, 2961–2964, https://doi.org/10.1007/s10072-021-05106-4.
- 37 AbbVie Inc., Tool for Making Informed Decisions to Aid Timely Management of Parkinson′s Disease (MANAGE-PD), AbbVie Inc., North Chicago, IL, USA, 2021, https://www.managepd.com/.
- 38 Tsuboi Y., Nakagawa R., and Ishido M., The quality of life burden in advanced Parkinson’s disease applying “5-2-1” diagnosing criteria: subgroup analyses of the JAQPAD (Japanese QOL survey of Parkinson’s disease) study, European Journal of Neurology. (2019) 26, no. S1.
- 39 Tsuboi Y., Ishido M., Watanabe J., Thakkar S., Jalundhwala Y. J., Kukreja P., Kratochvil D., Bao Y., and Pahwa R., Off-time independently affects to QOL in advanced Parkinson’s disease (APD) patients, but not in non-APD patients; an explanatory analysis of the JAQPAD study, European Journal of Neurology. (2020) 27, no. S1.
